ORR* to

immunotherapy in patients subgroups CheckMate 067

Patients with  PDL1>5% respond well to

both combination Ipi +Nivo or Nivo alone.

Patients wild type respond better to combination Nivo+ IPI than to Nivo alone.


Finally patients with lower LDH have respond the best to both treatments (combi or mono).

Efficacy of treatments for the total number of patients is known from ASCO2015 -median PFS is 11.5 months for NIVO + IPI versus 6.9 months for NIVO alone and 2.9 months for IPI alone.
* - overall response rate